Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient took two doses of Vivotif consecutively, instead of taking the first two doses every other day; Case reference number US-BN-2024-002019 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV24-1309) on 07-Jun-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication were not provided. On 06-Jun-2024, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, via oral use for unknown indication. On 07-Jun-2024, one day after the first dose the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, via oral use (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240607-71c867 to US-BAVARIAN NORDIC A/S-US-BN-2024-002019, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender took the second dose of Vivotif, one day after the first dose, at an unknown dose, via oral use which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unknown age and gender took the second dose of Vivotif, one day after the first dose, at an unknown dose, via oral use which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.